Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07149220 · ClinicalTrials.gov registry record · Phase 1
Fenretinide Mucoadhesive Patch: Evaluation of Oral Cancer Prevention Efficacy in Adults With Premalignant Oral Lesions.
A Phase 1 study of Oral Leukoplakia and Oral Dysplasia, sponsored by Ohio State University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT07149220 is a Phase 1 study of Oral Leukoplakia and Oral Dysplasia that is actively recruiting participants, run by Ohio State University. The registered enrollment target is 25 participants, below the 44-participant average among 4 other Oral Leukoplakia trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07149220, a Phase 1 study of Oral Leukoplakia and Oral Dysplasia, is actively recruiting participants, sponsored by Ohio State University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to determine the effect of a mucoadhesive system that releases the vitamin A derivative, fenretinide (FMS), on precancerous surface epithelial (lining tissue inside your mouth) changes. Specifically, does application of the FMS induce specific changes: 1) reduction in the clinical size, 2) reduction in the histologic grade of precancerous changes (determined by microscopic examination), 3) reduce the nuclear LOH events (changes in copy number of key genes to prevent oral cancer). The first part of this study entails a single FMS application to persons having their wisdom teeth removed. This study is done to confirm how long the FMS needs to remain in place to release the cancer-preventive agent. Participants will: 1) Have the FMS applied over the impacted wisdom tooth for 15 minutes, 2) FMS is removed, saliva is collected, and blood is drawn from a vein in the arm. 3) Tissue overlying the impacted wisdom tooth is removed and analyzed. The second, multi-FMS application entails patients who have precancerous oral surface epithelial changes. These patients will have: 1) a piece of the precancerous tissue removed (biopsy) and examined under a microscope to ensure the diagnosis. Blood is drawn from a vein in the arm., 2) One week after the biopsy, return to discuss the results. If the changes are precancerous, this person will be given FMS to apply to the site twice a day. 3) Patients return every 7 to 10 days (for a total of six weeks) for an oral exam and clinical pictures, return the FMS, and obtain new FMS for the upcoming week., 4) At week 3 (midway), blood is drawn from a vein in the arm., 5) After the six weeks of treatment, clinical pictures are obtained, blood is drawn from a vein in the arm and all of the remaining treated tissue is completely removed. The patient is securely contacted and results are discussed. 6) Approximately 6 weeks after the final surgery, patients return for a complete oral examination and clinical pi
Conditions Studied
Interventions
- DRUG Mucoadhesive fenretinide-releasing system (FMS)
Study Locations (1)
Ohio
- Ohio State University College of Dentistry - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-09-01 |
| Est. Completion | 2026-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07149220
The ClinicalTrials.gov registry entry for NCT07149220 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 44-participant average among 4 other Oral Leukoplakia trials with a reported enrollment target (43% lower). The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Oral Leukoplakia appearing as the primary indexed condition, and to 1 intervention - of which Mucoadhesive fenretinide-releasing system (FMS) is the first listed.
NCT07149220 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT07149220 about?
NCT07149220 is a clinical study titled "Fenretinide Mucoadhesive Patch: Evaluation of Oral Cancer Prevention Efficacy in Adults With Premalignant Oral Lesions.". The goal of this clinical trial is to determine the effect of a mucoadhesive system that releases the vitamin A derivative, fenretinide (FMS), on precancerous surface epithelial (lining tissue inside your mouth) changes. Specifically, does application of the FMS induce specific changes: 1) reduction...
What is the current status of trial NCT07149220?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2025-09-01. Estimated completion is 2026-08-30.
What conditions does trial NCT07149220 study?
This clinical trial studies the following conditions: Oral Leukoplakia, Oral Dysplasia.
What interventions are being tested in trial NCT07149220?
The interventions under investigation include: Mucoadhesive fenretinide-releasing system (FMS) (DRUG).
Who is sponsoring clinical trial NCT07149220?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07149220 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oral Leukoplakia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia
RECRUITING · Phase 2
-
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion
ACTIVE NOT RECRUITING · Phase 2
-
Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia
ACTIVE NOT RECRUITING · Phase 2
-
Biomarkers for Oral Cancer
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.